The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48 of a daily regimen of Atazanavir (ATV)/ Ritonavir (RTV)HS 300/100 mg combined with either one additional drug [Lamivudine (3TC) 300 mg daily] or 2 additional drugs [Tenofovir/Emtricitabine(TDF/FTC) 300/200 mg daily].
Article source: http://clinicaltrials.gov/ct2/show/NCT01620944?term=hiv&lup_s=05%2F17%2F2012&lup_d=30
Related posts
- Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
- Tenofovir gel dropped from HIV prevention trial in women because it was not effective
- Interactions Between HIV and Malaria in African Children
- VOICE HIV prevention trial to discontinue use of tenofovir tablets - News
- First Efficacy Trial Of A Microbicide Ring To Prevent HIV Is Underway
- Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load Monitoring
- Steady State PK in Malnourished HIV Infected Children
- Evaluating the Safety, Tolerance, Drug Interactions, and Effective Dosing of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in ART-Naive Children Infected With HIV and TB
- The Effect of Atazanavir and Ritonavir on the Pharmacokinetics of Oral Norethindrone
- Treatment Can Stop HIV/AIDS in its Tracks
